<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0409234110
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AZI-ONCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        50.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Azi-Once&trade; is one of a group of antibiotics called macrolides.<br />It is used to treat infections caused by certain bacteria and other<br />micro-organisms, which include:<br />&bull; Chest, throat or nasal infections (such as bronchitis, pneumonia,<br />tonsillitis, sore throat (pharyngitis) and sinusitis).<br />&bull; ear infections.<br />&bull; skin and soft tissue infections (such as an abscess or boil).<br />&bull; sexually transmitted diseases caused by an organism called<br />chlamydia.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; you are allergic to Azi-Once&trade; or any other macrolide antibiotic<br />such as erythromycin or clarithromycin or any of the ingredients<br />listed in section 6. An allergic reaction may cause skin rash or<br />wheezing.<br />&bull; you are taking any ergot derivatives such as ergotamine (used to<br />treat migraine) as these medicines should not be taken together with<br />Azi-Once&trade;.<br />Take special care with Azi-Once&trade;<br />Your doctor needs to know before you take Azi-Once&trade; if you have<br />or have had any of the following conditions:<br />&bull; kidney problems. &bull; heart conditions.<br />&bull; liver problems: your doctor may need to monitor your liver<br />function or stop the treatment.<br />&bull; and if you are taking any ergot derivatives such as ergotamine<br />(used to treat migraine) as these medicines should not be taken<br />together with Azi-Once&trade;.<br />Tell your doctor immediately if you feel your heart beating in your<br />chest or have an abnormal heartbeat, or get dizzy or faint or suffer<br />from any muscle weakness when taking Azi-Once&trade;.<br />Prolonged cardiac repolarization and QT interval, imparting a risk of<br />developing cardiac arrhythmia and torsades de pointes, have been<br />seen in treatment with macrolides, including azithromycin. Cases of<br />torsades de pointes have been spontaneously reported during<br />postmarketing surveillance in patients receiving azithromycin.<br />Providers should consider the risk of QT prolongation which can be<br />fatal when weighing the risks and benefits of azithromycin for at-risk<br />groups including:<br />&bull; patients with known prolongation of the QT interval, a history of<br />torsades de pointes, congenital long QT syndrome, bradyarrhythmias<br />or uncompensated heart failure.<br />&bull; patients on drugs known to prolong the QT interval.<br />&bull; patients with ongoing proarrhythmic conditions such as uncorrected<br />hypokalemia or hypomagnesemia, clinically significant bradycardia,<br />and in patients receiving Class IA (quinidine, procainamide) or Class<br />III (dofetilide, aminodarone, sotalol) antiarrhythmic agents. Elderly<br />patients may be more susceptible to drug-associated effects on the<br />QT interval.<br />If you develop diarrhoea or loose stools during or after treatment, tell<br />your doctor at once. Do not take any medicine to treat your diarrhoea<br />without first checking with your doctor. If your diarrhoea continues,<br />please inform your doctor.<br />Taking other medicines<br />Tell your doctor before taking Azi-Once&trade;, if you are taking any of<br />the medicines listed below:<br />&bull; ergot or ergotamine-see &lsquo;Take special care&rsquo; section.<br />&bull; warfarin or any similar medicine to prevent blood clots.<br />&bull; ciclosporin (used to suppress the immune system to prevent and<br />treat rejection of a transplanted organ or bone marrow).<br />&bull; antacids (for indigestion).<br />&bull; digoxin (used to treat heart failure).<br />&bull; terfenadine (for hay fever or a skin allergy).<br />You should always tell your doctor if you are taking or have recently<br />taken any other medicines including those obtained without a<br />prescription.<br />Taking Azi-Once&trade; with food and drink<br />You should take Azi-Once&trade; either 1 hour before a meal or 2 hours<br />after a meal.<br />Pregnancy and breast-feeding<br />If you are pregnant, trying to get pregnant or are breast-feeding you<br />should not take Azi-Once&trade; without discussing it with your doctor<br />first.<br />Driving and using machines<br />Azi-Once&trade; is not expected to affect your ability to drive or use<br />machines.<br />Important information about some of the ingredients of<br />Azi-Once&trade;<br />Azi-Once&trade; contains lactose, a type of sugar. If you have an<br />intolerance to some sugars contact your doctor before taking&nbsp;Azi-Once&trade;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Azi-Once&trade; exactly as your doctor has told you.<br />You should check with your doctor or pharmacist if you are not sure.<br />The capsules should be swallowed whole.<br />The usual dose in adults and children over 45 kg is 500mg<br />(2 capsules) taken together, once a day, for 3 days. For some diseases<br />such as Chlamydia the dose is 1g (4 capsules) taken all together on<br />one day only.<br />Azi-Once&trade; capsules should not be taken by children weighing less<br />than 45kg.<br />You should tell your doctor if you have kidney or liver problems as<br />your doctor may need to alter the normal dose.<br />Doctors sometimes prescribe different doses to these. The label on<br />the pack will tell you which dose you should take. If you are still not<br />sure, ask your doctor or pharmacist.<br />Always continue with the course even if you feel better. If your<br />infection gets worse or you do not start to feel better within a few<br />days or a new infection develops, go back and see your doctor.<br />If you take more Azi-Once&trade; than you should<br />If you take too much Azi-Once&trade; you may feel unwell. Tell your<br />doctor or contact your nearest hospital casualty department<br />immediately.<br />If you forget to take Azi-Once&trade;<br />If you forget to take Azi-Once&trade; take it as soon as you can. Take<br />your next dose at the right time. Do not take a double dose to make<br />up for a forgotten dose.</p><p>If you stop taking Azi-Once&trade;<br />If you stop taking Azi-Once&trade; too soon, the infection may return.<br />Take the capsules for the full time of treatment, even when you<br />begin to feel better.<br />If you have any further questions about the use of this product, ask<br />your doctor or pharmacist for advice.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines Azi-Once&trade; can cause side effects although not<br />everybody gets them. Tell your doctor immediately if you<br />experience any of the following symptoms after taking this<br />medicine as the symptoms can be severe.<br />&bull; sudden wheeziness, difficulty in breathing, swelling of eyelids,<br />face or lips, rash or itching (especially affecting the whole body).<br />&bull; severe or prolonged diarrhoea, which may have blood or mucus<br />in it, during or after treatment with Azi-Once&trade; as this may be a<br />sign of serious bowel inflammation.<br />&bull; severe skin rash causing redness and flaking.<br />&bull; rapid or irregular heartbeat.<br />&bull; low blood pressure.<br />The most common side effects that occur when taking Azi-Once&trade;<br />are listed below. These may go away during treatment as your body<br />adjusts to the medicine. Tell your doctor if any of these side effects<br />continue to bother you.<br />Very common side effects<br />(occurring in at least 1 in 10 people taking Azi-Once&trade;):<br />Stomach cramps, feeling sick, diarrhoea, wind.<br />Common side effects (likely to occur in less than 1 in 10 people):<br />Dizziness, headache, numbness or pins and needles, being sick,<br />indigestion, loss of appetite, taste disturbance, visual disturbances,<br />deafness, skin rash and /or itching, joint pain, low numbers of<br />lymphocytes (type of white blood cells), higher number of<br />eosinophils (type of white blood cells), low blood bicarbonate and<br />tiredness or weakness.</p><p>Uncommon side effects that occur in less than 1 in 100 people<br />taking Azi-Once&trade; are:<br />Yeast infections of the mouth and vagina (thrush), low numbers of<br />leukocytes (type of white blood cells), low number of neutrophils<br />(type of white blood cells), allergic reactions of various severity,<br />blistering of the skin, mouth, eyes and genitals, skin more sensitive<br />to sunlight than normal, feeling nervous, reduced sense of touch or<br />sensation (hypoesthesia), sleepness or sleeplessness (insomnia),<br />poor hearing or ringing in the ears, heart palpitations, chest pain,<br />constipation, stomach pain associated with diarrhoea and fever,<br />inflammation of the liver (hepatitis), changes in liver enzymes,<br />general loss of strength, swelling, general discomfort and abnormal<br />laboratory test values (e.g. blood or liver tests).<br />Rare side effects that occur in less than 1 in 1,000 people taking<br />Azi-Once&trade; are:<br />Agitation, vertigo and changes in liver function.<br />Other side effects that have been reported, but it is not known<br />how frequently they occur:<br />Fits or fainting, aggression or anxiety, feeling hyperactive,<br />localised muscle weakness, loss of smell or altered sense of smell,<br />loss of taste, tongue discolouration, inflammation of the pancreas<br />(pancreatitis), inflammation of the kidney or kidney failure,<br />yellowing of the skin or eyes (jaundice) or liver failure (rarely<br />life-threatening), bruising or prolonged bleeding after injury,<br />blistering of the skin, severe skin reaction and abnormal<br />electrocardiogram (ECG).<br />If any of the side effects get serious, or if you notice any side<br />effects not listed in this leaflet, please tell your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 OC.<br />&bull; Do not use after the expiry date (EXP) which is stated on the<br />&nbsp; &nbsp;blister and the carton.<br />&bull; Medicines should not be disposed of via waste water or<br />&nbsp; &nbsp;household waste. Ask your pharmacist how to dispose of medicines<br />&nbsp; &nbsp;no longer required. This will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each capsule contains the active substance: 262.05 mg<br />azithromycin dihydrate equivalent to 250 mg of azithromycin.<br />The other ingredients are: Lactose anhydrous, magnesium stearate,<br />maize starch, sodium lauryl sulfate, titanium dioxide and gelatin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Azi-Once™ 250mg Capsules: White opaque cap and white opaque
body printed 'Jamjoom' on cap in black and 'Azi 250' on body in
black, filled with white off white powder.
Azi-Once™ 250mg Capsules: Available in pack contains 6
capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,</p><p>Jeddah,</p><p>Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and<br />Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last reviewed in 09/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي أزي- ونس إلى فئة من المضادات الحيوية تسمى الماكروليد. يستخدم لعلاج العدوى التي<br />تسببها بعض أنواع البكتيريا والجسيمات الدقيقة الأخرى وتشمل:<br />&bull; العدوى الصدرية وعدوى الحلق والأنف ( مثل الالتهاب الشعبي والالتهاب الرئوي والتهاب اللوزتين<br />واحتقان الحلق (التهاب البلعوم) والتهاب الجيوب الانفية.<br />&bull; عدوى الأذن.<br />&bull; عدوى الجلد والأنسجة الرخوة ( مثل الخراج والدمامل).<br />&bull; الأمراض المنقولة جنسيا والتي يسببها جسيم يسمى الكلاميديا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم أزي- ونس<br />أو أي مضاد حيوي آخر من نوع الماكروليد مثل إريثرومايسين&nbsp;&nbsp;كان لديك حساسية ضد أزي- ونس<br />أو كلاريثرومايسين أو أي من مكونات الدواء الأخرى المذكورة في الجزء رقم ٦ بهذه النشرة</p><p>. التفاعلالتحسسي من الممكن أن يسبب طفح جلدي أو صفير.<br />&bull; إذا كنت تتناول أي من مشتقات الإرجوت مثل إرجوتامين (يستخدم لعلاج الصداع النصفي) حيث أنه<br />.&trade; يحظر استخدام هذه الادوية بجانب أزي- ونس<br />بحذر &trade; استخدم أزي- ونس<br />يحتاج الطبيب أن يعرف إذا كنت أنت أو طفلك تنطبق عليك أي من الحالات الآتية قبل استخدامك ل&nbsp;أزي- ونس:<br />&bull; كان لديك مشاكل في الكلى. &bull; كان لديك مشاكل في القلب. كنت مصابا بمرض السكري.<br />&bull; كان لديك مشاكل في الكبد: قد يحتاج الطبيب لمراقبة وظائف الكبد لديك أو وقف العلاج.<br />&bull; إذا كنت تتناول أي من مشتقات الإرجوت مثل إرجوتامين (يستخدم لعلاج الصداع النصفي) حيث أنه<br />. يحظر استخدام هذه الادوية بجانب أزي- ونس<br />أخبر طبيبك إذا شعرت بضربات قلبك في الصدر أو إذا شعرت بأي ضربات قلب غير طبيعية أو إذا<br />.شعرت بالدوار أو الإغماء أو إذا كنت تعاني من وهن في العضلات عند استخدامك ل أزي- ونس<br />وقد شوهدت مع العلاج بالماكروليدات بما في ذلك أزيثرومايسين عودة اطالة الاستقطاب للقلب وتسرع<br />القلب متباين قوة النبض، مما يضفي خطرعدم انتظام ضربات القلب. وقد سجلت عفويا خلال المراقبة<br />بعد التسويق حالات تسرع القلب متباين قوة النبض في المرضى الذين يتلقون أزيثروميسين.<br />تسرع القلب متباين قوة النبض التي يمكن أن تكون (QT) ينبغي للمزودين النظر في مخاطر إطالة<br />قاتلة عندما تزن المخاطر والمنافع من أزيثروميسين للفئات المعرضة للخطر بما في ذلك:<br />تسرع القلب متباين قوة النبض، أو تاريخ من (QT) &bull; المرضى الذين يعانون من إطالة فترة<br />الخلقية، بطئ ضربات القلب أو قصور القلب غير (QT) متلازمة إطالة فترة ،torsades de pointes<br />المعوض.<br />(QT) &bull; المرضى على الأدوية المعروفة بإطالة فترة<br />&bull; المرضى الذين يعانون من ظروف حالية لقبل عدم انتظام ضربات القلب مثل حالات نقص بوتاسيوم<br />الدم غير المصححة، نقص مغنيزيوم الدم، بطء القلب الواضح سريريا، والمرضى الذين يتلقون في<br />كينيدين، بروكاينأميد) أو من الدرجة الثالثة (دوفيتليد، امينودارون، سوتالول) ادوية مضادات ) AI فئة<br />ارتفاع معدل ضربات القلب.<br />.(QT) قد يكون المرضى المسنين أكثر عرضة للآثار الادوية المرتبطة بفترة<br />إذا حدث إسهال أو براز ناعم أثناء استخدام الدواء، أخبر طبيبك على الفور. لا تأخذ دواء لعلاج<br />الإسهال قبل مراجعة الطبيب أولاً. إذا استمر الإسهال يجب عليك إخبار طبيبك.<br />تحدث إلى طبيبك قبل تناول أزيثروميسين إذا كنت:<br />&bull; تم تشخيصك بمرض عصبي ، وهو مرض يصيب الدماغ أو الجهاز العصبي.<br />&bull; لديك مشاكل عقلية أو عاطفية أو سلوكية.<br />&bull; لديهم حالة تعرف باسم الوهن العضلي الوبيل ، مع التعب والإرهاق للعضلات: أزيثروميسين قد يزيد<br />أعراض الوهن العضلي سوءا أو يسببها .<br />&bull; لا ينصح باستخدام أزيثروميسين للمرضى دون سن ٦ أشهر من العمر.<br />كينيدين ، ) IA المرضى الذين يستخدمون أدوية لعلاج عدم انتظام ضربات القلب من فئة<br />دوفتيليدي ، أمينوديلون ، السوتالول) التي تستخدم لعلاج الإيقاعات غير ) III بروكاييناميد) أو الفئة<br />الطبيعية في القلب) ، سيسابريد (يستخدم لعلاج مشاكل المعدة) أو تيرفينادين (مضاد للهستامين يستخدم<br />لعلاج الحساسية): لا ينصح بإستخدام أزيثروميسين معهم.<br />استخدم الأدوية الأخرى<br />إذا كنت أنت أو طفلك تتناول أي من الأدوية&nbsp;التالية&nbsp;أخبر طبيبك قبل أن تتناول أو تعطي لطفلك أزي- ونس<br />&nbsp;إرجوت أو إرجوتامين (انظر الجزء: استخدم أزي- ونس<br />&bull; الوارفارين أو أي أدوية مماثلة تمنع تجلط الدم.<br />&bull; سايكلوسبورين ( يستخدم للتخفيض من عمل الجهاز المناعي لمنع رفض الجسم لزرع عضو أو نخاع<br />عظام).<br />&bull; مضادات الحموضة (لحالات عسر الهضم).<br />&bull; ديجوكسين (يستخدم في علاج السكتة القلبية).<br />&bull; زيدوفودين ، نلفينافير (يستخدم في علاج فيروس نقص المناعة البشرية).<br />&bull; استاتين (مثل أتورفاستاتين ، يستخدم لخفض الدهون في الدم).<br />&bull; ريبوفلافين (يستخدم في علاج العدوى البكتيرية بما في ذلك السل).<br />&bull; سيسابريد (يستخدم لعلاج مشاكل في المعدة).<br />&bull; استيميزول، تيرفينادين (مضادات الهيستامين المستخدمة لعلاج تفاعلات الحساسية).<br />&bull; الفنتانيل (مسكن للألم).<br />&bull; فلوكونازول (للالتهابات الفطرية).<br />&bull; الكولشيسين (يستخدم لعلاج النقرس وحمى البحر الأبيض المتوسط).<br />يجب دائما إخبار طبيبك إذا كنت تتناول أو تناولت منذ فترة وجيزة أي دواء آخر بما في ذلك الادوية<br />التي تتناولها بدون وصفة طبية.<br />استخدام أزي- ونس مع الطعام أو الشراب<br />لا يتأثر أزي- ونس بالطعام أو الشراب&nbsp;<br />الحمل والإرضاع</p><p>إذا كنتِ حاملاً أو تخططين للحمل أو كنتِ مرضعة ، لا يجب عليك تناول أزي- ونس&nbsp;قبل مراجعة الطبيب أولاً.<br />قيادة المركبات وتشغيل المعدات<br />&nbsp; ليس من المتوقع أن يؤثر أزي- ونس على قدرتك على قيادة المركبات وتشغيل المعدات.</p><p>&nbsp;معلومات هامة حول بعض مكونات أزي- ونس<br />يحتوى هذا الدواء علي السكروز وهو نوع من انواع السكريات ( ۳٫٦۹ جم في كل ٥ مل). إذا أخبرك&nbsp;الطبيب أن لديك حساسية ضد بعض أنواع السكريات،&nbsp;يرجى استشارته قبل استخدام أزي- ونس إذا كنت مريض بالسكري يجب أن تضع ذلك في الحسبان فيما يخص نظامك الغذائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عليك تناول أزي- ونس تماما كما أخبرك الطبيب. إذا لم تكن متأكدا يرجى&nbsp;&nbsp;<br />مراجعة الطبيب أو الصيدلي. يجب ابتلاع الكبسولات كاملة.<br />الجرعة المعتادة بالنسبة للبالغين والأطفال الذين يزنون أكثر من ٤٥ كجم هي<br />٥۰۰ ملجم (كبسولتين) يتم تناولهم سوياً مرة واحدة يومياً ولمدة ۳ أيام.<br />في بعض الامراض مثل الكلاميديا (المتدثرات) تكون الجرعة ۱ جم<br />٤ كبسولات) تؤخذ سوياً مرة واحدة فقط. )<br />يجب عدم إستخدام كبسولات أزي- ونس مع الأطفال الذين يزنون أقل من&nbsp;٤٥ كجم.<br />يجب عليك إخبار الطبيب إذا كنت تعاني من أي مشاكل في الكبد والكلى حيث أن<br />ذلك قد يؤدي لتعديل الجرعة الاعتيادية.<br />في بعض الأحيان يقوم الأطباء بتحديد جرعات مختلفة عن الجرعات السابقة.<br />الملصق على العبوة سوف يخبرك عن الجرعة التي ينبغى عليك تناولها. إذا كنت<br />لا تزال غير متأكد استشر طبيبك أو الصيدلي.<br />يجب عليك إكمال عدد الجرعات المطلوبة حتى لو شعرت بالتحسن. إذا تدهورت<br />العدوى أو إذا لم تشعر بالتحسن خلال أيام قليلة أو إذا ظهرت عدوى جديد فقم<br />بمراجعة الطبيب.<br />إذا تناولت أزي- ونس بكمية أكثر مما ينبغي &trade;<br />فمن الوارد أن تشعر بالتوعك. أخبر طبيبك أو اتصل بقسم الحوادث في أقرب مستشفى على الفور.&nbsp;إذا تناولت كمية كبيرة من أزي- ونس<br /><br />إذا نسيت أن تتناول أزي- ونس<br />إذا نسيت أن تتناول جرعة أزي- ونس في موعدها فقم بتناولها فور أن تتذكر&nbsp;<br />وقم بتناول الجرعة التالية لها في موعدها الصحيح. لا تقم بتناول ضعف الجرعة<br />لتعويض جرعة فائتة.</p><p>إذا توقفت عن تناول أزي- ونس<br />إذا توقفت عن تناول أزي- ونس بشكل مبكر جدا فمن الوارد أن تعود العدوى من جديد&nbsp;<br />. يجب عليك تناول كبسولات أزي- ونس&nbsp;خلال الوقت الكامل المحدد للدواء حتى لو شعرت بالتحسن قبل انقضاء هذا الوقت.<br />إذا كان لديك المزيد من الاستفسارات حول كيفية إستخدام الدواء، استشر طبيبك<br />أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع كل الأدوية، يمكن ل أزي- ونس أن يتسبب في تأثيرات جانبية &trade;<br />ولكنها لا تصيب كل الأشخاص.<br />أخبر طبيبك على الفور إذا لاحظت ظهور أي من الأعراض التالية عند إستخدام<br />حيث أنه من الممكن أن تكون الأعراض حادة &trade; أزي- ونس<br />- صفير مفاجئ، صعوبة في التنفس، انتفاخ جفون العين أو الوجه او الشفاة، طفح<br />جلدي أو حكة (وبخاصة التي تصيب كامل الجسم).<br />- إسهال حاد أو مستمر من الممكن أن يحتوى على مخاط أو دم أثناء إستخدام<br />أو بعد إستخدامه حيث أن هذه الأعراض قد تكون علامة على &trade; أزي- ونس<br />التهاب خطير في الأمعاء.<br />- طفح جلدي حاد يسبب احمرار وتقشر.<br />- سرعة أو عدم انتظام في ضربات القلب.<br />- انخفاض ضغط الدم.<br />موجودة في القائمة أدناه. &trade; الآثار الجانبية الاكثر شيوعا عند إستخدام أزي- ونس<br />قد تختفي هذه الأعراض خلال فترة العلاج حيث يتأقلم الجسم مع الدواء.<br />أخبر طبيبك إذا بدأت تشعر بالضيق بسبب هذه الأعراض.<br />الآثار الجانبية الشائعة جدا (تحدث في حالة على الأقل من إجمالي ۱۰ أشخاص<br />يتعاطون الدواء):<br />تقلصات معوية، شعور بالغثيان، إسهال، ريح.<br />الآثار الجانبية الشائعة (تحدث في أقل من ۱ من ۱۰ أشخاص يتعاطون الدواء):<br />دوخة، صداع، تنميل أو شعور بالوخز، قئ، عسر هضم، فقدان الشهية<br />واضطراب في حاسة التذوق، اضطراب في الرؤية، صمم، طفح جلدي او حكة،<br />ألم في المفاصل، انخفاض في عدد الخلايا اللمفاوية (نوع من أنواع خلايا الدم<br />وهي نوع من أنواع خلايا الدم (eosinophils) البيضاء)، زيادة عدد الحمضات<br />البيضاء، انخفاض البيكربونات في الدم، تعب و وهن.<br />الآثار الجانبية غير الشائعة (تحدث في أقل من ۱ من ۱۰۰ أشخاص يتعاطون<br />الدواء):<br />عدوى فطرية في الفم أو المهبل (القلاع)، انخفاض عدد نوع من أنواع خلايا الدم<br />البيضاء يسمى (ليكوسايت)، انخفاض عدد خلايا العدلات (نوع من أنواع خلايا<br />الدم البيضاء)، تفاعل تحسسي متنوع الحدة، تبثر الجلد، الفم، العين، الأعضاء<br />التناسلية، ازدياد حساسية الجلد لضوء الشمس بشكل غير طبيعي، احساس<br />بالعصبية والتوتر، انخفاض في حاسة اللمس أو الإحساس، نعاس أو عدم القدرة<br />على النوم (الأرق)، ضعف السمع أو طنين في الأذن، خفقان القلب، ألم في<br />الصدر، إمساك، ألم في المعدة مصحوب بحمى وإسهال، التهاب كبدي، تغير في<br />إنزيمات الكبد، فقدان عام للقوة، تورم، شعور بعدم الارتياح بشكل عام و نتائج<br />فحوصات معملية غير طبيعية ( مثل فحوصات الدم والكبد).<br />الآثار الجانبية النادرة (تحدث في أقل من ۱ من ۱۰۰۰ أشخاص يتعاطون<br />الدواء):<br />تهيج، دوار و تغير في وظائف الكبد.<br />آثار جانبية أخرى بمعدل تكرار غير معروف (لا يمكن توقعها من البيانات<br />المتاحة)<br />تشنجات أو إغماء، عدوانية أو قلق، فرط الحركة، فقدان أو تغير في حاسة الشمس<br />وفقدان حاسة التذوق، تغير لون اللسان، التهاب البنكرياس، التهاب الكلى أو الفشل<br />الكلوي، اصفرار الجلد أو العين (الصفراء) أو فشل كبدي (نادرا ما يكون مهددا<br />للحياة)، كدمات أو طول النزف بعد الإصابات، تبثر الجلد ، تفاعل جلدي حاد و<br />مخطط كهربية قلب (رسم قلب) غير طبيعي .<br />إذا وصلت أي من هذه الآثار الجانبية لدرجة الخطورة أو لاحظت ظهور آثار<br />جانبية أخرى لم تذكر في هذه النشرة، يرجى استشارة الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.<br />&bull; يحفظ فى درجة حرارة لا تزيد عن ۳۰ &deg;م.<br />&bull; لا تتناول بعد انتهاء فترة صلاحيتها المكتوب على الشريط وعلى العلبة.<br />&bull; اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها .لا ينبغي<br />التخلص من الأدوية عبر إلقائها فى بالوعات الصرف أو فى مخلفات المنزل.<br />ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل كبسولة تحتوي علي المادة الفعالة : ۲٦۲٫۰٥ ملجم ازيثرومايسين دايهايدريت<br />والمكافئة ل ( ۲٥۰ ملجم ازيثرومايسين).<br />المكونات الأخرى هي: لاكتوز لامائي، ستيارات ماغنسيوم، نشا الذرة، كبريتات<br />لوريل الصوديوم، ثاني أكسيد التيتانيوم و جيلاتين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><br />كبسولات أزي- ونس ۲٥۰ ملجم: ذات جزء علوي أبيض غير شفاف وجزء &trade; آخر سفلي أبيض غير شفاف مطبوع عليها كلمة&nbsp; &#39;Jamjoom&#39;<br />على الجزء العلوي ,و كلمة Azi250&nbsp;على الجزء السفلي باللون الأسود، كبسولات جيلاتينية صلبة&nbsp;مملوءة ببودرة لونها أبيض إلى مائل للأبيض .<br /><br />أزي- ونس۲٥۰ ملجم كبسولات متوفرة في عبوة تحتوى علي ٦ كبسولات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدوية، جدة، المملكة العربية السعودية<br />- الهاتف: 608111-12-966+ فاكس :&nbsp;608222-12-966+<br />الموقع الإلكتروني:&nbsp;www.jamjoompharma.com&nbsp;<br />للإبلاغ عن أي أثار جانبيه:<br />&bull; المملكة العربية السعودية:<br />المركز الوطني للتيقظ و السلامة الدوائية<br />- فاكس: 7662-205-11-966+&nbsp;<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.<br />هاتف: 22228302-11-966+ تحويلة: 2317-2356-2353-2354-2334-2340<br />الهاتف المجاني: 8002490000<br />بريد إلكتروني:&nbsp;npc.drug@sfda.gov.sa<br />الموقع الالكتروني:&nbsp;www.sfda.gov.sa/npc<br />&bull; دول الخليج الأخرى:<br />الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azi once 250 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains azithromycin dihydrate equivalent to 250 mg azithromycin.
Excipients with known effect:
Each capsule contains lactose anhydrous.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule.
White opaque cap and white opaque body printed 'jamjoom' on cap in black and 'Azi 250' on body in
black, size '0' hard gelatin capsules filled with white off white powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azithromycin is indicated for the treatment of the following infections when known or likely to be due<br />to one or more susceptible microorganisms (see section 5.1):<br />- bronchitis<br />- community-acquired pneumonia<br />- sinusitis<br />- pharyngitis/tonsillitis (see section 4.4 regarding streptococcal infections)<br />- otitis media<br />- skin and soft tissue infections<br />- uncomplicated genital infections due to Chlamydia trachomatis and Neisseria gonorrhoeae.<br />Considerations should be given to official guidance regarding the appropriate use of antibacterial<br />agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology:<br />Azithromycin capsules should be given as a single daily dose.<br />In common with many other antibiotics Azithromycin capsules should be taken at least 1 hour before or<br />2 hours after food.</p><p>Children over 45 kg body weight and adults, including elderly patients:<br />The total dose of azithromycin is 1500 mg which should be given over three days (500 mg once daily).<br />In uncomplicated genital infections due to Chlamydia trachomatis, the dose is 1000 mg as a single oral<br />dose. For susceptible Neisseria gonorrhoeae the recommended dose is 1000 mg or 2000 mg of</p><p>azithromycin in combination with 250 mg or 500 mg ceftriaxone according to local clinical treatment<br />guidelines. For patients who are allergic to penicillin and/or cephalosporins, prescribers should consult<br />local treatment guidelines.<br />Paediatric population:<br />In children under 45 kg body weight: Azithromycin capsules are not suitable for children under 45kg.<br />Renal impairment:<br />No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 10 - 80ml/min).</p><p>Caution should be exercised when azithromycin is administered to patients with severe renal<br />impairment (GFR &lt; 10 ml/min) (see section 4.4 and section 5.2).<br />Hepatic impairment:<br />Since azithromycin is metabolised in the liver and excreted in the bile, the drug should not be given to<br />patients suffering from severe liver disease. No studies have been conducted regarding treatment of<br />such patients with azithromycin (see section 4.4).<br />Method of administration:<br />Azithromycin capsules are for oral administration only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azithromycin is contra-indicated in patients with a known hypersensitivity to azithromycin,
erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients (listed in section 6.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity<br />As with erythromycin and other macrolides, serious allergic reactions including angioneurotic oedema<br />and anaphylaxis (rarely fatal), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)<br />have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and<br />required a longer period of observation and treatment.</p><p>Hepatotoxicity<br />Since the liver is the principal route of elimination for azithromycin, the use of azithromycin should be<br />undertaken with caution in patients with significant hepatic disease. Cases of fulminant hepatitis<br />potentially leading to life-threatening liver failure have been reported with azithromycin (see section<br />4.8). Some patients may have had pre-existing hepatic disease or may have been taking other<br />hepatotoxic medicinal products.<br />In case of signs and symptoms of liver dysfunction, such as rapid developing asthenia associated with<br />jaundice, dark urine, bleeding tendency or hepatic encephalopathy, liver function tests/ investigations<br />should be performed immediately. Azithromycin administration should be stopped if liver dysfunction<br />has emerged.</p><p>Ergot derivatives<br />In patients receiving ergot derivatives, ergotism has been precipitated by co-administration of some<br />macrolide antibiotics. There are no data concerning the possibility of an interaction between ergot and<br />azithromycin. However, because of the theoretical possibility of ergotism, azithromycin and ergot<br />derivatives should not be co-administrated.<br />Prolongation of the QT interval<br />Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and<br />torsades de pointes, have been seen in treatment with other macrolides. A similar effect with<br />azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac<br />repolarisation (see section 4.8); therefore caution is required when treating patients:<br />&bull; With congenital or documented QT prolongation<br />&bull; Currently receiving treatment with other active substance known to prolong QT interval such as<br />antiarrhythmics of Classes Ia and III, cisapride and terfenadine<br />&bull; With electrolyte disturbance, particularly in case of hypokalaemia and hypomagnesemia<br />&bull; With clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency.<br />Superinfection<br />As with any antibiotic preparation, observation for signs of superinfection with non-susceptible<br />organisms including fungi is recommended.</p><p>Clostridium difficile associated diarrhoea<br />Clostridium difficile associated diarrhoea (CDAD) has been reported with the use of nearly all<br />antibacterial agents, including azithromycin, and may range in severity from mild diarrhoea to fatal<br />colitis. Strains of C. difficile producing hypertoxin A and B contribute to the development of CDAD.<br />Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections<br />can be refractory to antimicrobial therapy and may require colectomy. Therefore, CDAD must be<br />considered in patients who present with diarrhoea during or subsequent to the administration of any<br />antibiotics. Careful medical history is necessary since CDAD has been reported to occur over 2 months<br />after the administration of antibacterial agents. Discontinuation of therapy with azithromycin and the<br />administration of specific treatment for C. difficile should be considered.</p><p>Streptococcal infections<br />Penicillin is usually the first choice for treatment of pharyngitis/tonsillitis due to Streptococcus<br />pyogenes and also for prophylaxis of acute rheumatic fever. Azithromycin is in general effective against<br />streptococcus in the oropharynx, but no data are available that demonstrate the efficacy of azithromycin<br />in preventing acute rheumatic fever.</p><p>Renal impairment:<br />In patients with severe renal impairment (GFR &lt;10 ml/min) a 33% increase in systemic exposure to<br />azithromycin was observed (see section 5.2).</p><p>Myasthenia gravis<br />Exacerbations of the symptoms of myasthenia gravis and new onset of myasthenia syndrome have been<br />reported in patients receiving azithromycin therapy (see section 4.8).</p><p>Diabetes<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose<br />malabsorption should not take this medicine.<br />This medicinal product contains sulphur dioxide which may rarely cause severe hypersensitivity<br />reactions and bronchospasm.<br />Azithromycin capsules are for oral administration only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antacids: In a pharmacokinetic study investigating the effects of simultaneous administration of<br />antacid with azithromycin, no effect on overall bioavailability was seen, although peak serum<br />concentrations were reduced by approximately 24%. In patients receiving both azithromycin and<br />antacids, the drugs should not be taken simultaneously.</p><p>Cetirizine: In healthy volunteers, co-administration of a 5-day regimen of azithromycin with 20 mg<br />cetirizine at steady-state resulted in no pharmacokinetic interaction and no significant changes in the<br />QT interval.<br />Didanosine (Dideoxyinosine): Co-administration of 1200 mg/day azithromycin with 400 mg/day<br />didanosine in six HIV-positive subjects did not appear to affect the steady-state pharmacokinetics of<br />didanosine as compared to placebo.</p><p>Digoxin: Some of the macrolide antibiotics have been reported to impair the microbial metabolism of<br />digoxin in the gut in some patients. In patients receiving concomitant azithromycin, a related azalide<br />antibiotic, and digoxin the possibility of raised digoxin levels should be borne in mind.</p><p>Zidovudine: Single 1000 mg doses and multiple 1200 mg or 600 mg doses of azithromycin had little<br />effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite.<br />However, administration of azithromycin increased the concentrations of phosphorylated zidovudine,<br />the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this<br />finding is unclear, but it may be of benefit to patients.<br />Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not<br />believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other<br />macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex<br />does not occur with azithromycin.</p><p>Ergot derivatives: Due to the theoretical possibility of ergotism, the concurrent use of azithromycin<br />with ergot derivatives is not recommended (see section 4.4).<br />Pharmacokinetic studies have been conducted between azithromycin and the following drugs known to<br />undergo significant cytochrome P450 mediated metabolism.</p><p>Atorvastatin: Co-administration of atorvastatin (10 mg daily) and azithromycin (500 mg daily) did not<br />alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition assay).</p><p>Carbamazepine: In a pharmacokinetic interaction study in healthy volunteers, no significant effect was<br />observed on the plasma levels of carbamazepine or its active metabolite in patients receiving<br />concomitant azithromycin.</p><p>Cimetidine: In a pharmacokinetic study investigating the effects of a single dose of cimetidine, given 2<br />hours before azithromycin, on the pharmacokinetics of azithromycin, no alteration of azithromycin<br />pharmacokinetics was seen.</p><p>Coumarin-type oral anticoagulants: In a pharmacokinetic interaction study, azithromycin did not<br />alter the anticoagulant effect of a single dose of 15 mg warfarin administered to healthy volunteers.<br />There have been reports received in the post-marketing period of potentiated anticoagulation<br />subsequent to co-administration of azithromycin and coumarin-type oral anticoagulants. Although a<br />causal relationship has not been established, consideration should be given to the frequency of<br />monitoring prothrombin time when azithromycin is used in patients receiving coumarin-type oral<br />anticoagulants.</p><p>Ciclosporin: In a pharmacokinetic study with healthy volunteers who were administered a 500 mg/day<br />oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose of<br />ciclosporin, the resulting ciclosporin Cmax and AUC0-5 were found to be significantly elevated (by 24%<br />and 21% respectively), however no significant changes were seen in AUC0-&infin;. Consequently, caution<br />should be exercised before considering concurrent administration of these drugs. If co-administration of<br />these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</p><p>Efavirenz: Co-administration of a single dose of 600 mg azithromycin and 400 mg efavirenz daily for<br />7 days did not result in any clinically significant pharmacokinetic interactions.</p><p>Fluconazole: Co-administration of a single dose of 1200 mg azithromycin did not alter the<br />pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life of azithromycin<br />were unchanged by the co-administration of fluconazole, however, a clinically insignificant decrease in<br />Cmax (18%) of azithromycin was observed.</p><p>Indinavir: Co-administration of a single dose of 1200 mg azithromycin had no statistically significant<br />effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for 5 days.</p><p>Methylprednisolone: In a pharmacokinetic interaction study in healthy volunteers, azithromycin had<br />no significant effect on the pharmacokinetics of methylprednisolone.<br />Midazolam: In healthy volunteers, co-administration of 500mg/day azithromycin for 3 days did not<br />cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single dose of<br />15mg midazolam.</p><p>Nelfinavir: Co-administration of azithromycin (1200 mg) and nelfinavir at steady state (750 mg three<br />times daily) resulted in increased azithromycin concentrations. No clinically significant adverse effects<br />were observed and no dose adjustment was required.</p><p>Rifabutin: Co-administration of azithromycin and rifabutin did not affect the serum concentrations of<br />either drug. Neutropenia was observed in subjects receiving concomitant treatment of azithromycin and<br />rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to<br />combination with azithromycin has not been established (see section 4.8.).</p><p>Sildenafil: In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500<br />mg daily for 3 days) on the AUC and Cmax, of sildenafil or its major circulating metabolite.</p><p>Terfenadine: Pharmacokinetic studies have reported no evidence of an interaction between<br />azithromycin and terfenadine. There have been rare cases reported where the possibility of such an<br />interaction could not be entirely excluded; however there was no specific evidence that such an<br />interaction had occurred.</p><p>Theophylline: There is no evidence of a clinically significant pharmacokinetic interaction when<br />azithromycin and theophylline are co-administered to healthy volunteers.</p><p>Triazolam: In 14 healthy volunteers, co-administration of 500mg azithromycin on Day 1 and 250 mg<br />on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the pharmacokinetic<br />variables for triazolam compared to triazolam and placebo.</p><p>Trimethoprim/sulfamethoxazole: Co-administration of trimethoprim/sulfamethoxazole DS (160<br />mg/800 mg) for 7 days with 1200mg azithromycin on Day 7 had no significant effect on peak<br />concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole.<br />Azithromycin serum concentrations were similar to those seen in other studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Animal reproduction studies have been performed at doses up to moderately maternally toxic dose<br />concentrations. In these studies, no evidence of harm to the foetus due to azithromycin was found.<br />There are, however, no adequate and well-controlled studies in pregnant women. Because animal</p><p>reproduction studies are not always predictive of human response, azithromycin should be used during<br />pregnancy only if clearly needed.</p><p><u>Breast-feeding</u><br />There are no data on secretion in breast milk. As many drugs are excreted in human milk, azithromycin<br />should not be used in the treatment of a lactating woman unless the physician feels that the potential<br />benefits justify the potential risks to the infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence to suggest that Azithromycin may have an effect on a patient&#39;s ability to drive or<br />operate machinery</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azithromycin is well tolerated with a low incidence of side effects.<br />The section below lists the adverse reactions identified through clinical trial experience and<br />postmarketing surveillance by system organ class and frequency. Adverse reactions identified from<br />post-marketing experience are included in italics. The frequency grouping is defined using the<br />following convention: Very common (&ge;1/10); Common (&ge; 1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to<br />&lt;1/100); Rare (&ge; 1/10,000 to &lt;1/1,000); Very Rare (&lt; 1/10,000); and Not known (cannot be estimated<br />from the available data). Within each frequency grouping, undesirable effects are presented in order of<br />decreasing seriousness.<br />Adverse reactions possibly or probably related to azithromycin based on clinical trial experience<br />and post-marketing surveillance:</p><p>Infections and Infestations<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Candidiasis, oral candidiasis, vaginal infection<br />Not known (cannot be estimated from available data)<br />Pseudomembranous colitis (see section 4.4)</p><p>Blood and Lymphatic System Disorders<br />Uncommon (&ge; 1/1,000 to &lt; 1/100)<br />Leukopenia, neutropenia<br />Not known (cannot be estimated from available data)<br />Thrombocytopenia, haemolytic anaemia</p><p>Immune System Disorders<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Angioedema, hypersensitivity<br />Not known (cannot be estimated from available data)<br />Anaphylactic reaction (see section 4.4)</p><p>Metabolism and Nutrition Disorders<br />Common (&gt; 1/100, &lt; 1/10)<br />Anorexia</p><p>Psychiatric Disorders<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Nervousness<br />Rare (&gt; 1/10000, &lt; 1/1000)<br />Agitation<br />Not known (cannot be estimated from available data)<br />Aggression, anxiety</p><p>Nervous System Disorders<br />Common (&gt; 1/100, &lt; 1/10)<br />Dizziness, headache, paraesthesia, dysgeusia<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Hypoaesethesia, somnolence, insomnia<br />Not known (cannot be estimated from available data)<br />Syncope, convulsion, psychomotor hyperactivity, anosmia, ageusia, parosmia, Myasthenia gravis (see<br />section 4.4).</p><p>Eye Disorders<br />Common (&gt; 1/100, &lt; 1/10)<br />Visual impairment<br />Ear and Labyrinth Disorders<br />Common (&gt; 1/100, &lt; 1/10)<br />Deafness<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Hearing impaired, tinnitus<br />Rare (&gt; 1/10000, &lt; 1/1000)<br />Vertigo</p><p>Cardiac Disorders<br />Uncommon (&ge;1/1,000 to &lt;1/100)<br />Palpitations<br />Not known (cannot be estimated from available data)<br />Torsades de pointes (see section 4.4), arrhythmia (see section 4.4) including ventricular tachycardia</p><p>Vascular Disorders<br />Not known (cannot be estimated from available data)<br />Hypotension</p><p>Gastrointestinal Disorders<br />Very common (&ge;1/10)<br />Diarrhoea, abdominal pain, nausea, flatulence<br />Common (&gt; 1/100, &lt; 1/10)<br />Vomiting, dyspepsia<br />Uncommon (&gt; 1/1000, &lt; 1/100)<br />Gastritis, constipation<br />Not known (cannot be estimated from available data)<br />Pancreatitis, tongue discolouration</p><p>Hepatobiliary Disorders<br />Uncommon (&gt; 1/1000, &lt; 1/100)<br />Hepatitis<br />Rare (&gt; 1/10000, &lt; 1/1000)<br />Hepatic function abnormal<br />Not known (cannot be estimated from available data)<br />Hepatic failure (see section 4.4), which has rarely resulted in death, hepatitis fulminant, hepatic<br />necrosis, jaundice cholestatic</p><p>Skin and Subcutaneous Tissue Disorders<br />Common (&gt; 1/100, &lt; 1/10)<br />Pruritus and rash<br />Uncommon (&gt; 1/1000, &lt; 1/100)<br />SJS, photosensitivity reaction, urticarial<br />Very Rare (&lt; 1/10,000)<br />DRESS<br />Not known (cannot be estimated from available data)<br />TEN, erythema multiforme</p><p>Musculoskeletal, Connective Tissue Disorders<br />Common (&gt; 1/100, &lt; 1/10)<br />Arthralgia</p><p>Renal and Urinary Disorders<br />Not known (cannot be estimated from available data)<br />Renal failure acute, nephritis interstitial</p><p>General disorders and Administration Site Conditions<br />Common (&gt; 1/100, &lt; 1/10)<br />Fatigue<br />Uncommon (&gt; 1/1000, &lt; 1/100)</p><p>Chest pain, oedema, malaise, asthenia</p><p>Investigations<br />Common (&gt; 1/100, &lt; 1/10)<br />Lymphocyte count decreased, eosinophil count increased, blood bicarbonate decreased<br />Uncommon (&gt; 1/1000, &lt; 1/100)<br />Aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased,<br />blood urea increased, blood creatinine increased, blood potassium abnormal<br />Not known (cannot be estimated from available data)<br />Electrocardiogram QT prolonged (see section 4.4)</p><p>To reports any side effect(s):<br />Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>Other GCC States:</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events experienced in higher than recommended doses were similar to those seen at normal<br />doses. The typical symptoms of an overdose with macrolide antibiotics include reversible loss of<br />hearing, severe nausea, vomiting and diarrhoea. In the event of overdose, the administration of<br />medicinal charcoal and general symptomatic treatment and supportive measures are indicated as<br />required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General properties<br />Pharmacotherapeutic group: Antibacterials for systemic use. ATC code: J01FA10<br /><u>Mode of action:</u><br />Azithromycin is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by<br />adding a nitrogen atom to the lactone ring of erythromycin A. The chemical name of azithromycin is 9-<br />deoxy-9a-aza-9a-methyl-9a-homoerythromycin A. The molecular weight is 749.0. The mechanism of<br />action of azithromycin is based upon the suppression of bacterial protein synthesis by means of binding<br />to the ribosomal 50S sub-unit and inhibition of peptide translocation.</p><p><u>Mechanism of resistance:</u><br />Resistance to azithromycin may be inherent or acquired. There are three main mechanisms of resistance<br />in bacteria: target site alteration, alteration in antibiotic transport and modification of the antibiotic.<br />Azithromycin demonstrates cross resistance with erythromycin resistant gram positive isolates. A<br />decrease in macrolide susceptibility over time has been noted particularly in Streptococcus<br />pneumoniae and Staphylococcus aureus. Similarly, decreased susceptibility has been observed<br />among Streptococcus viridans and Streptococcus agalactiae (Group B) streptococcus against other<br />macrolides and lincosamides.<br />Breakpoints<br />Azithromycin susceptibility breakpoints for typical bacterial pathogens, as published by EUCAST are:</p><table cellspacing="0" cellpadding="2" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="2" style="vertical-align:middle"><p><strong>Organism</strong></p></td><td colspan="2" rowspan="" style="vertical-align:middle"><p><strong>MIC breakpoints (mg/L)</strong></p></td></tr><tr><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Susceptible (S&le;)</strong></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p><strong>Resistant (R&gt;)</strong></p></td></tr><tr><td colspan="" rowspan=""><p><em>Staphylococcus</em>&nbsp;spp.</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>1</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>2</p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus</em>&nbsp;groups A, B, C and G</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.25</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.5</p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus pneumoniae</em></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.25</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.5</p></td></tr><tr><td colspan="" rowspan=""><p><em>Haemophilus influenzae</em></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.12</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>4</p></td></tr><tr><td colspan="" rowspan=""><p><em>Moraxella catarrhalis</em></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.25</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.5</p></td></tr><tr><td colspan="" rowspan=""><p><em>Neisseria gonorrhoeae</em></p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.25</p></td><td colspan="" rowspan="" style="vertical-align:middle"><p>0.5</p></td></tr></tbody></table><p>Susceptibility<br />The prevalence of acquired resistance may vary geographically and with time for selected species and<br />local information on resistance is desirable, particularly when treating severe infections. As necessary,<br />expert advice should be sought when the local prevalence of resistance is such that the utility of the<br />agent in at least some types of infections is questionable.<br />Table: Antibacterial spectrum of Azithromycin</p><table cellspacing="0" cellpadding="2" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p><em>Staphylococcus aureus</em></p><p>Methycillin-susceptible</p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus pneumoniae</em></p><p>Penicillin-susceptible</p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus pyogenes&nbsp;</em><strong>(Group A)</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Aerobic Gram-negative microorganisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p><em>Haemophilus influenzae</em></p><p><em>Haemophilus parainfluenzae</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Legionella pneumophila</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Neisseria gonorrhoeae</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Pasteurella multocida</em></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Anaerobic microorganisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p><em>Clostridium perfringens</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Fusobacterium spp.</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Prevotella spp.</em></p></td></tr><tr><td colspan="" rowspan=""><p><em>Porphyromonas spp.</em></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Other microorganisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p><em>Chlamydia trachomatis</em></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p><em>Streptococcus pneumoniae</em></p><p>Penicillin-intermediate</p><p>Penicillin-resistant</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p><em>Enterococcus faecalis</em></p></td></tr><tr><td colspan="" rowspan=""><p>Staphylococci&nbsp;<strong>MRSA, MRSE</strong>*</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Anaerobic microorganisms</strong></p></td></tr><tr><td colspan="" rowspan=""><p>Bacteroides fragilis group</p></td></tr></tbody></table><p>* Methycillin-resistant staphylococci have a very high prevalence of acquired resistance to macrolides<br />and have been placed here because they are rarely susceptible to azithromycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Bioavailability after oral administration is approximately 37%. Peak plasma concentrations are attained<br />2 to 3 hours after taking the medicinal product.</p><p>Distribution<br />Orally administered azithromycin is widely distributed throughout the body. In pharmacokinetic studies<br />it has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably</p><p>higher (as much as 50 times) than those measured in plasma, which indicates that the agent strongly<br />binds to tissues.<br />Binding to serum proteins varies according to plasma concentration and ranges from 12% at 0.5<br />microgram/ml up to 52% at 0.05 microgram azithromycin/ml serum. The mean volume of distribution<br />at steady state (VVss) has been calculated to be 31.1 l/kg.<br />Elimination<br />The terminal plasma elimination half-life closely reflects the elimination half-life from tissues of 2-4<br />days.<br />Approximately 12% of an intravenously administered dose of azithromycin is excreted unchanged in<br />urine within the following three days. Particularly high concentrations of unchanged azithromycin have<br />been found in human bile. Also in bile, ten metabolites were detected, which were formed through Nand<br />O- demethylation, hydroxylation of desosamine and aglycone rings and cleavage of cladinose<br />conjugate. Comparison of the results of liquid chromatography and microbiological analyses has shown<br />that the metabolites of azithromycin are not microbiologically active.<br />In animal tests, high concentrations of azithromycin have been found in phagocytes. It has also been<br />established that during active phagocytosis higher concentrations of azithromycin are released from<br />inactive phagocytes. In animal models this results in high concentrations of azithromycin being<br />delivered to the site of infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Phospholipidosis (intracellular phospholipid accumulation) has been observed in several tissues (e.g.<br />eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) of mice, rats, and dogs<br />given multiple doses of azithromycin. Phospholipidosis has been observed to a similar extent in the<br />tissues of neonatal rats and dogs. The effect has been shown to be reversible after cessation of<br />azithromycin treatment. The significance of the finding for animals and humans is unknown.</p><p>Carcinogenic potential:<br />Long-term studies in animals have not been performed to evaluate carcinogenic potential as the drug is<br />indicated for short-term treatment only and there were no signs indicative of carcinogenic activity.</p><p>Mutagenic potential:<br />There was no evidence of a potential for genetic and chromosome mutations in in-vivo and in-vitro test<br />models.</p><p>Reproductive toxicity:<br />In animal studies for embryotoxic effects of the substance, no teratogenic effect was observed in mice<br />and rats. In rats, azithromycin doses of 100 and 200 mg/kg bodyweight/day led to mild retardation of<br />foetal ossification and in maternal weight gain. In peri- and postnatal studies in rats, mild retardation<br />following treatment with 50 mg/kg/day azithromycin and above was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize Starch<br />Sodium Lauryl Sulfate<br />Magnesium Stearate<br />Lactose Anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months (3 years)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azithromycin capsules are available as:<br />Pack of 6 capsules. Aluminium-PVC/PVDC blister</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JAMJOOM PHARMACEUTICALS CO.
P.O. Box 6267
Jeddah 21442
Tel: 6081111
Fax: 6081222.
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13- Nov- 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>